MNTR Mentor Capital Inc (QB)

Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer
Immunotherapy Index appreciated 101.7% during the first three quarters of 2013.
The equally weighted Cancer Immunotherapy Index is regularly benchmarked
against the appreciation of the average of the NASDAQ, S&P, and NYSE
Biotech Indices. For the same 2013 YTD period  the biotech indices averaged a 46.0%
gain. 

Inovio (314%) and Celldex (428%) have
led the sector in gains during the January thru September 2013 period. Celldex
($2,865 Million) represents 56% of the market capitalization of the fifteen
member Cancer Immunotherapy Index which has a combined total share value of $5.1
Billion. 

The Mentor Capital Cancer Immunotherapy Index companies and their
performance for the first thirty-nine weeks of 2013 follow: Galena Biopharma
Corporation (NASDAQ:GALE) +49.02%, NewLink Genetics Corporation (NASDAQ:NLNK) +50.24%,  Vical Incorporated (NASDAQ:VICL)  -57.90%, 
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)  +314.41%, Dendreon (NASDAQ:DNDN) -44.61%, Immunocellular
Therapeutics, Ltd. (NYSE MKT:IMUC) +33.85%,  Agenus (NASDAQ:AGEN) -32.44%,  Oncothyreon (NASDAQ:ONTY) +7.29%, Biovest
International (OTCMKTS:BVTIQ) -100.00%, Celldex Therapeutics (NASDAQ:CLDX) +428.02%,
Northwest Biotherapeutics (NASDAQ:NWBO) +7.71%, CEL ? SCI Corp. (NYSEMKT:CVM) -37.04%
, Generex Biotechnology (OTCBB:GNBT) +28.00% as a proxy for its wholly-owned
immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc.
(OTCMKTS:PVCT) +37.50% and Advaxis, Inc. (OTCBB:ADXSD) +49.33%  -  all
for an average 2013 YTD gain of +101.68%. 
(Annualized rate: +135.44%).

Mentor Capital, Inc., by acquisition or stock purchase,
seeks to invest in leading-edge private and public cancer companies, and
certain other situations. Mentor created the Cancer Immunotherapy Index July
10, 2009.  Since then, it has invested or
maintained a tracking position in all companies in the Cancer Immunotherapy
Index which can be found at  www.MentorCapital.com.   

Forward Looking Statements, Safe Harbor and Risk
Descriptions are Incorporated by Reference from the MNTR Company Web Site
above.

For further information contact:

Chester Billingsley, CEO                   

Mentor Capital, Inc.

(760) 788 - 4700 

Mentor Capital (QB) (USOTC:MNTR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Mentor Capital (QB) (USOTC:MNTR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024